Role of symmetric and asymmetric division of stem cells in developing drug resistance.
Often, resistance to drugs is an obstacle to a successful treatment of cancer. In spite of the importance of the problem, the actual mechanisms that control the evolution of drug resistance are not fully understood. Many attempts to study drug resistance have been made in the mathematical modeling literature. Clearly, in order to understand drug resistance, it is imperative to have a good model of the underlying dynamics of cancer cells. One of the main ingredients that has been recently introduced into the rapidly growing pool of mathematical cancer models is stem cells. Surprisingly, this all-so-important subset of cells has not been fully integrated into existing mathematical models of drug resistance. In this work we incorporate the various possible ways in which a stem cell may divide into the study of drug resistance. We derive a previously undescribed estimate of the probability of developing drug resistance by the time a tumor is detected and calculate the expected number of resistant cancer stem cells at the time of tumor detection. To demonstrate the significance of this approach, we combine our previously undescribed mathematical estimates with clinical data that are taken from a recent six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myelogenous leukemia. Based on our analysis we conclude that leukemia stem cells must tend to renew symmetrically as opposed to their healthy counterparts that predominantly divide asymmetrically.
Tomasetti
Cristian
C
Applied Mathematics, Statistics, and Scientific Computation Program, Department of Mathematics and Center for Scientific Computation and Mathematical Modeling, University of Maryland, College Park, MD 20742, USA. cristian@math.umd.edu
Levy
Doron
D
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D002455:Cell Division; D019008:Drug Resistance, Neoplasm; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008954:Models, Biological; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate
Proc Natl Acad Sci U S A. 1989 Dec;86(23):9441-5
2687881
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10839-44
11517339
Blood. 1999 Sep 15;94(6):2056-64
10477735
Nature. 2005 Jun 30;435(7046):1267-70
15988530
Annu Rev Biochem. 2000;69:497-529
10966467
Genetics. 1943 Nov;28(6):491-511
17247100
Nature. 2006 Jun 29;441(7097):1068-74
16810241
Antibiot Chemother (1971). 1988;41:21-8
3245689
Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9714-9
15980154
Nature. 2006 Feb 2;439(7076):594-8
16357871
Math Biosci. 1999 Nov-Dec;162(1-2):1-32
10616278
Leukemia. 2009 Jun;23(6):1054-61
19282833
Cancer Res. 2005 Oct 1;65(19):8905-11
16204062
Nat Immunol. 2006 Nov;7(11):1225-33
17013390
Genetics. 2006 Apr;172(4):2557-66
16636113
Blood. 2006 Mar 1;107(5):2146-52
16249381
Cell Stem Cell. 2007 Nov;1(5):541-54
18345353
Theor Popul Biol. 2010 Feb;77(1):42-8
19896491
Nature. 2006 Aug 17;442(7104):818-22
16862118
Nat Med. 2006 Oct;12(10):1181-4
17013383
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1727-33
526911
Blood. 2001 Dec 15;98(13):3864-7
11739200
J Clin Invest. 2000 Jun;105(11):1493-9
10841502